Neuropeptides
DSIP
What is it?
DSIP is the abbreviation for delta sleep-inducing peptide, a nine-amino-acid peptide investigated in sleep research. Its name arose from experimental observations and should not be treated as a promise that it reliably induces sleep in people.
How it is studied
Studies have measured sleep architecture, sleep onset and subjective sleep quality. These are separate endpoints: a change in one measured feature does not necessarily mean better sleep or effective treatment of insomnia. Its functional biology is not reducible to a simple sedative mechanism.
What the evidence shows
Small human studies have reported differing results. A double-blind study in chronic insomnia concluded that short-term DSIP treatment was unlikely to provide major therapeutic benefit, because several measures, including subjective sleep quality, did not improve.
Limitations & safety context
The older, limited trial literature does not establish a routine insomnia therapy or the safety of long-term personal use. The supplied strengths have not been shown equivalent to a studied preparation. A sleep-related name and peptide identity are not sufficient grounds for a clinical claim.
Listed specifications
| Reference | Listed contents |
|---|---|
| DS5 | 5 mg |
| DS10 | 10 mg |
| DS15 | 15 mg |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.